Determination of the optimal detection time of circulating tumor cells for the postoperative monitoring of colorectal cancer

Huang,Tianchen; Xu,Cheng; Xiao,Jianan; Wang,Qingbing; Wang,Yanjun; Zhang,Yong; Bai,Dongxiao; Zhou,Fuyou; Zhao,Xiaoyu

doi:10.3892/ol.2020.11388

Determination of the optimal detection time of circulating tumor cells for the postoperative monitoring of colorectal cancer

Authors:
- Tianchen Huang
- Cheng Xu
- Jianan Xiao
- Qingbing Wang
- Yanjun Wang
- Yong Zhang
- Dongxiao Bai
- Fuyou Zhou
- Xiaoyu Zhao
View Affiliations

Affiliations: The Fourth Department of General Surgery, Anyang Tumor Hospital, Anyang, Henan 455000, P.R. China, Shanghai Biotecan Pharmaceuticals Co., Ltd., Shanghai Zhangjiang Institute of Medical Innovation, Shanghai 201204, P.R. China
Published online on: February 12, 2020 https://doi.org/10.3892/ol.2020.11388
Pages: 2996-3002

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Circulating tumor cells (CTCs) are widely used in cancer screening and monitoring. The present study focused on investigating the optimal time for the postoperative CTC detection in patients with colorectal cancer (CRC) to obtain more accurate results and facilitate subsequent treatment. By subtraction enrichment immunofluorescence in situ hybridization detection of CTCs, the present study demonstrated that different postoperative detection times in CRC substantially influenced the CTC numbers. In total, 134 subjects were enrolled. Among 10 healthy individuals and 20 preoperative patients with CRC, no CTCs were identified in the healthy subjects, and CTCs were detected in 85% (17/20) of the preoperative patients. In total, 104 postoperative patients with CRC (53 males and 51 females) with a mean average age of 57.63 years were studied. The total CTC detection rate was 81.73% (85/104) and the mean average CTC numbers in patients with tumor stage (T) T1, T2, T3 and T4 were 4.00, 3.33, 5.90 and 5.64 per 7.50 ml of peripheral blood, respectively. The CTC number trends in these four tumor stages within 5, 6, 7 and 10 postoperative days were variable, and were the most stable at 7 days. Gradual upward trends in CTC numbers were observed after 5, 6 and 7 postoperative days, and this upward trend was more obvious after 7 days. Overall, the findings of the present study suggest that CTC detection in CRC should be performed after at least 7 postoperative days rather than within 7 postoperative days.

View Figures

View References

1	Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, van de Velde CJ and Watanabe T: Colorectal cancer. Nat Rev Dis Primers. 1:150652015. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
3	Normanno N, Cervantes A, Ciardiello F, De Luca A and Pinto C: The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios. Cancer Treat Rev. 70:1–8. 2018. View Article : Google Scholar : PubMed/NCBI
4	Norcic G: Liquid biopsy in colorectal cancer-current status and potential clinical applications. Micromachines (Basel). 9(pii): E3002018. View Article : Google Scholar : PubMed/NCBI
5	Chu HY, Lu LS, Cho W, Wu SY, Chang YC, Lin CP, Yang CY, Lin CH, Jiang JK and Tseng FG: Enumerating circulating tumor cells with a Self-assembled cell array (SACA) Chip: A feasibility study in patients with colorectal cancer. Cancers (Basel). 11(pii): E562019. View Article : Google Scholar : PubMed/NCBI
6	Ashworth TR: A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Australian Med J. 14:146–147. 1869.
7	Wei RR, Sun DN, Yang H, Yan J, Zhang X, Zheng XL, Fu XH, Geng MY, Huang X and Ding J: CTC clusters induced by heparanase enhance breast cancer metastasis. Acta Pharmacol Sin. 39:1326–1337. 2018. View Article : Google Scholar : PubMed/NCBI
8	Klameth L, Rath B, Hochmaier M, Moser D, Redl M, Mungenast F, Gelles K, Ulsperger E, Zeillinger R and Hamilton G: Small cell lung cancer: Model of circulating tumor cell tumorospheres in chemoresistance. Sci Rep. 7:53372017. View Article : Google Scholar : PubMed/NCBI
9	Lee AW, Lin FX, Wei PL, Jian-Wei G and Chen JK: Binary-blend fibber-based capture assay of circulating tumor cells for clinical diagnosis of colorectal cancer. J Nanobiotechnology. 16:42018. View Article : Google Scholar : PubMed/NCBI
10	Chou WC, Wu MH, Chang PH, Hsu HC, Chang GJ, Huang WK, Wu CE and Hsieh JC: A prognostic model based on circulating tumour cells is useful for identifying the poorest survival outcome in patients with metastatic colorectal cancer. Int J Biol Sci. 14:137–146. 2018. View Article : Google Scholar : PubMed/NCBI
11	Yang C, Shi D, Wang S, Wei C, Zhang C and Xiong B: Prognostic value of pre- and post-operative circulating tumor cells detection in colorectal cancer patients treated with curative resection: A prospective cohort study based on ISET device. Cancer Manag Res. 10:4135–4144. 2018. View Article : Google Scholar : PubMed/NCBI
12	Wu F, Zhu J, Mao Y, Li X, Hu B and Zhang D: Associations between the Epithelial-mesenchymal transition phenotypes of circulating tumor cells and the clinicopathological features of patients with colorectal cancer. Dis Markers. 2017:94745322017. View Article : Google Scholar : PubMed/NCBI
13	Wang W, Wan L, Wu S, Yang J, Zhou Y, Liu F, Wu Z and Cheng Y: Mesenchymal marker and LGR5 expression levels in circulating tumor cells correlate with colorectal cancer prognosis. Cell Oncol (Dordr). 41:495–504. 2018. View Article : Google Scholar : PubMed/NCBI
14	Cai J, Huang L, Huang J, Kang L, Lin H, Huang P, Zhu P, Wang J, Dong J, Wang L and Xian CJ: Associations between the cyclooxygenase-2 expression in circulating tumor cells and the clinicopathological features of patients with colorectal cancer. J Cell Biochem. 120:4935–4941. 2019. View Article : Google Scholar : PubMed/NCBI
15	Andree KC, van Dalum G and Terstappen LW: Challenges in circulating tumor cell detection by the CellSearch system. Mol Oncol. 10:395–407. 2016. View Article : Google Scholar : PubMed/NCBI
16	Sheng Y, Wang T, Li H, Zhang Z, Chen J, He C, Li Y, Lv Y, Zhang J, Xu C, et al: Comparison of analytic performances of Cellsearch and iFISH approach in detecting circulating tumor cells. Oncotarget. 8:8801–8806. 2017. View Article : Google Scholar : PubMed/NCBI
17	Ye Z, Ding Y, Chen Z, Li Z, Ma S, Xu Z, Cheng L, Wang X, Zhang X, Ding N, et al: Detecting and phenotyping of aneuploid circulating tumor cells in patients with various malignancies. Cancer Biol Ther. 20:546–551. 2019. View Article : Google Scholar : PubMed/NCBI
18	Wu W, Zhang Z, Gao XH, Shen Z, Jing Y, Lu H, Li H, Yang X, Cui X, Li Y, et al: Clinical significance of detecting circulating tumor cells in colorectal cancer using subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH). Oncotarget. 8:21639–21649. 2017.PubMed/NCBI
19	O'Sullivan B, Brierley J, Byrd D, Bosman F, Kehoe S, Kossary C, Piñeros M, Van Eycken E, Weir HK and Gospodarowicz M: The TNM classification of malignant tumours-towards common understanding and reasonable expectations. Lancet Oncol. 18:849–851. 2017. View Article : Google Scholar : PubMed/NCBI
20	Chistiakov DA and Chekhonin VP: Circulating tumor cells and their advances to promote cancer metastasis and relapse, with focus on glioblastoma multiforme. Exp Mol Pathol. 105:166–174. 2018. View Article : Google Scholar : PubMed/NCBI
21	Zhou L, Dicker DT, Matthew E, El-Deiry WS and Alpaugh RK: Circulating tumor cells: Silent predictors of metastasis. F1000Res. 6(pii): F1000Faculty Rev. –1445. 2017.PubMed/NCBI
22	Stanesby O and Jenkins M: Comparison of the efficiency of colorectal cancer screening programs based on age and genetic risk for reduction of colorectal cancer mortality. Eur J Hum Genet. 25:832–838. 2017. View Article : Google Scholar : PubMed/NCBI